Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 T cells with Salvage ASCT in Multiple Myeloma
NCT02135406Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- May 2014
- Primary completion
- Sep 2015
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tisagenlecleucel in multiple myeloma (MM), sponsored by University of Pennsylvania. Primary endpoint: Number of Adverse Events at 2 years. Started May 2014; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02135406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135406.